drugset / Trial / NCT04920448

N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE

NCT04920448

Phase 2 Terminated 12 enrolled University Hospital, Caen
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to assess the safety of N-Acetylcysteine as a thrombolytic agent in acute ischemic stroke, especially regarding the risk of hemorrhagic transformation.

Timeline

Start
2021-06-16
Primary completion
2023-04-25
Completion
2024-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 150 mg/kg Intravenous

Indications